Oncology

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about prostate cancer, breast cancer, precision medicine, and gynecologic cancers.

Based on results of a cohort study that examined randomized clinical trials in 3 times periods, it is evident that efficacy measures and funding sources have dramatically changed over time.

CancerNetwork® spoke with Tzvia Bader about barriers between patients and appropriate clinical trials and how to combat these issues.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, molecular profiling, ovarian cancer, and more.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, and urothelial cancer.

ONCOLOGY co–Editor-in-Chief Julie M. Vose, MD, MBA, details how underrepresentation of racial and ethnic minorities in clinical trials negatively impacts the medical community and calls for greater inclusion by removing some barriers to participation.

CancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about prostate cancer, breast cancer, lung cancer, and more.

The medical oncologist and physician scientist based at the University of Texas MD Anderson Cancer Center explained recommendations for SARS-CoV-2 vaccination in patients participating in phase 1 oncology clinical trials.

The chief of urologic oncology at City of Hope spoke about how the COVID-19 pandemic has altered the way he cares for patients with cancer as well as how he believes it will continue to impact cancer prevention, detection, and treatment moving forward.

A cancer care expert from The Ohio State University Comprehensive Cancer Hospital talks about what patients and their providers need to know about the COVID-19 vaccine.

With an estimated 2.3 million new cases identified, the Global Cancer Statistics 2020 report indicated female breast cancer was the most commonly diagnosed cancer type.

CancerNetwork® spoke with the CEO of the Union for International Cancer Control to learn more about their efforts in oncology amidst the COVID-19 pandemic, and the work they are doing on World Cancer Day.

CancerNetwork® reviews the biggest news on initiatives and advancements in cancer care on World Cancer Day.

These findings have serious implications for future cancer care and underscore the need to resume cancer care and screening.

Age disparities in oncology trials are continuing, despite opposition to this issue.

Prostate cancer is the most frequent cancer found in American men, and the second leading cause of cancer death in this population. Currently, scores of reputable clinical trials are underway and recruiting patients.

Atezolizumab is an immune-checkpoint inhibitor, which has been approved by the US Food and Drug Administration (FDA) in various combinations for a number of cancer types in recent years.

Alan N. Peiris, MD spoke with ONCOLOGY about guidelines and strategies for treating patients who have had thyroid cancer. 

 The increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events  that have proven to be extremely challenging to manage.

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?

The US Food and Drug Administration recently approved gilteritinib (Xospata), in addition to final trial data from the phase 3 ADMIRAL trial, making it the new standard of care for acute myeloid leukemia.

Brain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.

Accuracy of current guidelines for genetic testing of breast cancer patients has been recently challenged by a pair of studies suggesting that these guidelines may miss as many patients with pathogenic variants (or genetic mutations) as they may catch.

ONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia. 

Despite the toll chemotherapy can take on the body, experts say it's possible for athletes to exercise while undergoing treatment for cancer.

Among 598 trials published between 2003 and 2018, only 107 had a female corresponding author, though women made up anywhere from 27% to 39% of academic oncologists during this time period. 

Had Charles Darwin lived in the late 20th century, he might have found amusement in contemplating the evolution of biomedical journals.